Zenta Tsuchihashi
Head Senior Director, Translational Safety, Clinical Safety & Pharmacovigilance Daiichi Sankyo
Zenta Tsuchihashi is Senior Director and Head of Translational Safety, Clinical Safety, and Pharmacovigilance at Daiichi Sankyo. He leads translational research focused on safety across the oncology portfolio, including work on drug-induced interstitial lung disease and antibody-drug conjugate safety. Previously, he served as Translational Science Lead for DS-8201 (ENHERTU), advancing biomarker development and translational strategies in oncology. Before Daiichi Sankyo, he held leadership roles at AstraZeneca, Novartis, and Bristol-Myers Squibb, contributing to biomarker discovery and clinical development across multiple cancer programs. With more than two decades in pharmaceutical research, he has extensive experience in translational science, biomarker development, and oncology drug development.
Seminars
Join this interactive roundtable to explore how non-specific ADC uptake into healthy tissues contributes to dose-limiting toxicities and what the industry can do to predict better, characterize, and mitigate these mechanisms early in development.
Join this discussion to examine how emerging mechanistic insights can be translated into safer ADC design strategies and improved therapeutic window by:
- Investigating non-specific ADC uptake pathways beyond macropinocytosis by leveraging CRISPR-Cas9 screening and healthy cell models to identify the receptors and endocytic mechanisms driving off-target toxicities
- Understanding how ADC physicochemical properties such as surface charge, hydrophobicity, linker stability, and DAR influence non-specific uptake into healthy tissues, and debating which design parameters offer the greatest opportunity for toxicity mitigation
- Translating mechanistic insights from fluorescent imaging, spatial biology, and clinically validated ADC safety data into predictive screening strategies that enable earlier candidate prioritization and improved therapeutic windows
